https://orcid.org/0000-0001-5249-3693
References
- European Medicines Agency. cabometyx-h-c-004163-ii-0005: EPAR - assessment report - variation. Amsterdam. 2019.
- Al Hussein M, Hotte SJ, Leong DP. Reversible cabozantinib-induced cardiomyopathy. Can J Cardiol. 2019;35(4):544.e1–544.e2.
- Lendvai N, Yee AJ, Tsakos I, et al. Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood. 2016;127(19):2355–2356.
- Iacovelli CR, Ciccarese C, Fornarini G, et al. Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. Br J Clin Pharmacol. 2019;85(6):1283–1289.
- Gronich N, Lavi I, Barnett-Griness O, et al. Tyrosine kinase-targeting drugs-associated heart failure. Br J Cancer. 2017;116(10):1366–1373.
- Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801.
- Hall PS, Harshman LC, Srinivas S, et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1(1):72–78.